New drug for prostate cancer patients in clinical trials
NXP800 shows promise for treating hormone‑therapy‑resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, thereby slowing tumor growth in preclinical models and early clinical trial settings.
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
Targeting heat shock proteins provides a new therapeutic angle for men whose advanced prostate cancer has become refractory to standard hormone‑based treatments, potentially extending survival and improving quality of life.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience